Angiotensin II and Cardiovascular-Renal Remodelling in Hypertension: Insights from a Human Model Opposite to Hypertension

详细信息    查看全文

• 作者：Verdiana Ravarotto ; Elisa Pagnin…
• 关键词：Rho kinase ; Nitric oxide ; Angiotensin II signaling ; Gitelman’s syndrome ; Bartter’s syndrome ; Cardiovascular ; renal remodeling
• 刊名：High Blood Pressure & Cardiovascular Prevention
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：22
• 期：3
• 页码：215-223
• 全文大小：514 KB
• 参考文献：1.Mehta PK, Griendling KK. Angiotensin II cell signaling. Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;92:C82-7.
  2.Nguyen Dinh Cat A, Touyz RM. Cell signaling of angiotensin II on vascular tone: novel mechanisms. Curr Hypertens Rep. 2011;13:122-.CrossRef PubMed
  3.Dzau VJ, Lopez-Ilasaca M. Searching for transcriptional regulators of Ang II induced vascular pathology. J Clin Invest. 2005;115:2319-2.PubMed Central CrossRef PubMed
  4.Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P, Morigi M, Coffman TM, Remuzzi G. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest. 2009;119:524-0.PubMed Central CrossRef PubMed
  5.Calò L, D’Angelo A, Cantaro S, Rizzolo M, Favaro S, Antonello A, Borsatti A. Intracellular calcium signalling and vascular reactivity in Bartter’s syndrome. Nephron. 1996;72:570-.CrossRef PubMed
  6.Calò LA, Schiavo S, Davis PA, Pagnin E, Mormino P, D’Angelo A, Pessina AC. Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. J Hypertens. 2010;28:111-.CrossRef PubMed
  7.Calò LA, Davis PA, Rossi GP. Understanding the mechanisms of angiotensin II signaling involved in hypertension and its long-term sequelae: insights from Bartter’s and Gitelman’s syndromes, human models of endogenous angiotensin II signaling antagonism. J Hypertens. 2014;32:2109-9.CrossRef PubMed
  8.Bartter FC, Pronove P, Gill JR, Maccardle RC. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. Am J Med. 1962;33:811-8.CrossRef PubMed
  9.Naesens M, Steels P, Verberckmoes R, Vanrenterghem Y, Kuypers D. Bartter’s and Gitelman’s syndromes: From gene to clinic. Nephron Physiol. 2004;96:65-8.CrossRef
  10.Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP. Bartter’s syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na–K-Cl cotransporter NKCC2. Nat Genet. 1996;13:183-.CrossRef PubMed
  11.Simon DB, Karet FE, Rodriguez-Soriano J, Hamdan JH, DiPietro A, Trachtman H, Sanjad SA, Lifton RP. Genetic heterogeneity of Bartter’s syndrome revealed by mutations in the K+ channel, ROMK. Nat Genet. 1996;14:152-.CrossRef PubMed
  12.Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R, Schurman S, Nayir A, Alpay H, Bakkaloglu A, Rodriguez-Soriano J, Morales JM, Sanjad SA, Taylor CM, Pilz D, Brem A, Trachtman H, Griswold W, Richard GA, John E, Lifton RP. Mutation in the chloride channel gene CLCNKB cause Bartter’s syndrome type III. Nat Genet. 1997;17:171-.CrossRef PubMed
  13.Gitelman HJ, Graham JB, Welt LG. A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Phys. 1966;79:221-5.PubMed
  14.Bettinelli A, Tosetto C, Colussi G, Tommasini G, Edefonti A, Bianchetti MG. Electrocardiogram with prolonged QT interval in Gitelman disease. Kidney Int. 2002;62:580-.CrossRef PubMed
  15.Scognamiglio R, Calò LA, Negut C, Coccato M, Mormino P, Pessina AC. Myocardial perfusion defects in Bartter and Gitelman syndromes. Eur J Clin Invest. 2008;38:888-5.CrossRef PubMed
  16.Favero M, Calò LA, Schiavon F, Punzi L. Bartter’s and Gitelman’s diseases. Best Pract Res Clin Rheumatol. 2011;25:637-8.CrossRef PubMed
  17.Vargas-Poussou R, Dahan K, Kahila D, Venisse A, Riveira-Munoz E, Debaix H, Grisart B, Bridoux F, Unwin R, Moulin B, Haymann JP, Vantyghem MC, Rigothier C, Dussol B, Godin M, Nivet H, Dubourg L, Tack I, Gimenez-Roqueplo AP, Houillier P, Blanchard A, Devuyst O, Jeunemaitre X. Spectrum of mutation in Gitelman syndrome. J Am Soc Nephrol. 2011;22:693-03.PubMed Central CrossRef PubMed
  18.Nguyen Dinh Cat A, Touyz RM. A new look at the renin-angiotensin system—focusing on the vascular system. Peptides. 2011;31:2141-0.CrossRef
  19.Crowley SD, Coffman TM. Recent advances involving the renin-angiotensin system. Exp Cell Res. 2012;318:1049-6.PubMed Central CrossRef PubMed
  20.Clementi E. Role of nitric oxide and its intracellular signalling pathways in the control of Ca2+ homeostasis. Biochem Pharmacol. 1998;55:713-.CrossRef PubMed
  21.Dzau VJ. Tissue angiotensin and pathobiology of vascular disease. A unifying hypothesis. Hypertension. 2001;37:1047-2.CrossRef PubMed
  22.Touyz RM, Schiffrin EL. Signal transduction Mechanisms Mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 2000;52:639-2.PubMed
  23.Calò LA, Ceolotto G, Milani M, Pagnin E, van den Heuvel LP, Sartori M, Davis PA, Costa R, Semplicini A. Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromes. Kidney Int. 2001;60:882-.CrossRef PubMed
  24.Calò LA, Davis PA, Semplicini A. Reduced content of alpha subunit of Gq-protein in monocytes of Bartter and Gitelman syndromes: relationship with vascu
• 作者单位：Verdiana Ravarotto (1)
  Elisa Pagnin (1)
  Antonio Fragasso (1)
  Giuseppe Maiolino (1)
  Lorenzo A. Calò (1)
  
  1. Department of Medicine, Nephrology and Hypertension, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy
  
• 刊物主题：Cardiology; Pharmacotherapy;
• 出版者：Springer International Publishing
• ISSN：1179-1985

文摘

Insights into the Angiotensin II (Ang II) signalling pathways have been provided by extensive studies using Bartter’s/Gitelman’s syndromes patients. These syndromes are characterized by activation of the renin-angiotensin-aldosterone system but do not develop hypertension and cardiovascular remodelling, therefore represent a mirror image of hypertension and clinically manifest themselves as the opposite of hypertension. The short and the long-term signalling of Ang II remain an important matter of investigation to shed light on mechanisms responsible for the pathophysiology of hypertension and its long-term complications, such as cardiovascular remodelling and atherogenesis. In particular the long-term signalling of Ang II is involved in the pathophysiology of cardiovascular-renal remodelling, inflammatory and hypertrophic responses in which the relationship between RhoA/Rho kinase pathway and NO system plays a crucial role. This review reports the results of our studies in Bartter’s and Gitelman’s syndromes to get better insight these processes and the role of Ang II signaling. The information obtained from the studies in Bartter’s/Gitelman’s patients can, in fact, clarify, confirm or be used to gather more general data on the biochemical mechanisms responsible for the pathophysiology of hypertension and its long-term complications and could contribute to identify additional potential significant targets of therapy. Keywords Rho kinase Nitric oxide Angiotensin II signaling Gitelman’s syndrome Bartter’s syndrome Cardiovascular-renal remodeling